C4 Therapeutics Showcases Progress on IKZF1/3 Degrader and Expanding Protein Degradation Pipeline

Reuters11-06

C4 <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Showcases Progress on IKZF1/3 Degrader and Expanding Protein Degradation Pipeline

C4 Therapeutics Inc. has provided an update on its clinical and preclinical pipeline, highlighting progress in targeted protein degradation therapies. The company is advancing cemsidomide, an IKZF1/3 degrader, with completed Phase 1 dose escalation in multiple myeloma (MM) and ongoing plans for Phase 2 trials in combination with dexamethasone. Data from Phase 1 studies in non-Hodgkin's lymphoma (NHL) and MM are expected to be presented at upcoming medical meetings. C4 Therapeutics also continues development of CFT8919 targeting EGFR L858R mutations and CFT1946 for BRAF V600 mutant solid tumors, while progressing early-stage programs through collaborations with Roche and MKDG. The company is building on a decade of experience in protein degradation to address a range of oncology and non-oncology indications. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. C4 Therapeutics Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581060323?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 20:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581060323","market":"us","top_or_hot":-1,"title":"C4 Therapeutics Showcases Progress on IKZF1/3 Degrader and Expanding Protein Degradation Pipeline","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      C4 <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Showcases Progress on IKZF1/3 Degrader and Expanding Protein Degradation Pipeline\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        C4 Therapeutics Inc. has provided an update on its clinical and preclinical pipeline, highlighting progress in targeted protein degradation therapies. The company is advancing cemsidomide, an IKZF1/3 degrader, with completed Phase 1 dose escalation in multiple myeloma (MM) and ongoing plans for Phase 2 trials in combination with dexamethasone. Data from Phase 1 studies in non-Hodgkin's lymphoma (NHL) and MM are expected to be presented at upcoming medical meetings. C4 Therapeutics also continues development of CFT8919 targeting EGFR L858R mutations and CFT1946 for BRAF V600 mutant solid tumors, while progressing early-stage programs through collaborations with Roche and MKDG. The company is building on a decade of experience in protein degradation to address a range of oncology and non-oncology indications. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. C4 Therapeutics Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>C4 Therapeutics Showcases Progress on IKZF1/3 Degrader and Expanding Protein Degradation Pipeline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nC4 Therapeutics Showcases Progress on IKZF1/3 Degrader and Expanding Protein Degradation Pipeline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 20:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      C4 <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Showcases Progress on IKZF1/3 Degrader and Expanding Protein Degradation Pipeline\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        C4 Therapeutics Inc. has provided an update on its clinical and preclinical pipeline, highlighting progress in targeted protein degradation therapies. The company is advancing cemsidomide, an IKZF1/3 degrader, with completed Phase 1 dose escalation in multiple myeloma (MM) and ongoing plans for Phase 2 trials in combination with dexamethasone. Data from Phase 1 studies in non-Hodgkin's lymphoma (NHL) and MM are expected to be presented at upcoming medical meetings. C4 Therapeutics also continues development of CFT8919 targeting EGFR L858R mutations and CFT1946 for BRAF V600 mutant solid tumors, while progressing early-stage programs through collaborations with Roche and MKDG. The company is building on a decade of experience in protein degradation to address a range of oncology and non-oncology indications. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. C4 Therapeutics Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CCCC","symbol_name":"C4 Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL2PwNwc:1","article_id":"2581060323","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581060323","pubTimestamp":1762431987,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"C4 Therapeutics Inc. has provided an update on its clinical and preclinical pipeline, highlighting progress in targeted protein degradation therapies. The company is advancing cemsidomide, an IKZF1/3 degrader, with completed Phase 1 dose escalation in multiple myeloma  and ongoing plans for Phase 2 trials in combination with dexamethasone. Data from Phase 1 studies in non-Hodgkin's lymphoma  and MM are expected to be presented at upcoming medical meetings. C4 Therapeutics also continues development of CFT8919 targeting EGFR L858R mutations and CFT1946 for BRAF V600 mutant solid tumors, while progressing early-stage programs through collaborations with Roche and MKDG. The company is building on a decade of experience in protein degradation to address a range of oncology and non-oncology indications. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to pr","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CCCC":"C4 Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"C4 Therapeutics展示了IKZF1/3降解剂和扩大蛋白质降解管道的进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CCCC":0.9},"content_text":"C4 Therapeutics Showcases Progress on IKZF1/3 Degrader and Expanding Protein Degradation Pipeline\n    \n\n        C4 Therapeutics Inc. has provided an update on its clinical and preclinical pipeline, highlighting progress in targeted protein degradation therapies. The company is advancing cemsidomide, an IKZF1/3 degrader, with completed Phase 1 dose escalation in multiple myeloma (MM) and ongoing plans for Phase 2 trials in combination with dexamethasone. Data from Phase 1 studies in non-Hodgkin's lymphoma (NHL) and MM are expected to be presented at upcoming medical meetings. C4 Therapeutics also continues development of CFT8919 targeting EGFR L858R mutations and CFT1946 for BRAF V600 mutant solid tumors, while progressing early-stage programs through collaborations with Roche and MKDG. The company is building on a decade of experience in protein degradation to address a range of oncology and non-oncology indications. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. C4 Therapeutics Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581060323","isCrawlerRequest":true}